<DOC>
	<DOCNO>NCT01030679</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness three dose CKD-501 compare placebo lower fast plasma glucose level people type 2 diabetes 8 week .</brief_summary>
	<brief_title>Evaluate Glycemic Control CKD-501 Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type Ⅱ diabetes mellitus Fasting Plasma Glucose ( FPG ) ≥ 126 ≤ 270 HbA1c 7 11 % Body mass index ( BMI ) range 2140 The patient take oral hypoglycemic agent diet therapy minimum 1 month Agreement write informed consent Type I diabetes , gestational diabetes secondary diabetes Treatment insulin ( 1month ) within 3 month Fasting Plasma Glucose level 270 mg/dl Triglyceride level 500 mg/dl Uncontrollable hypertension History myocardial infarction , heart failure , cerebral infarction , hematencephalon unstable angina within 6 month Severe hepatic dysfunction : AST , ALT , Total bilirubin , ALP level equal 3 time high upper normal limit ( UNL ) Severe renal dysfunction : Renal failure serum creatinine great 30 % normal limit Needs treatment acute disease , uncontrolled diseae diabetic complication In treatment concomitant drug severe risk drug interaction investigational drug History cancer within 5 year History drug abuse alcoholism Hepatitis B Antigen ( HBsAg ) test positive Treatment systemic inhalant corticosteroid within 1 month prior Screening Patient experience hypersensitivity reaction , serious adverse event effect treatment glitazones Fertile woman practice contraception appropriate method Pregnant woman nurse mother Has contraindication treatment investigational drug medical psychogenic side Participated trial within 4 week Participating trial present An impossible one participate clinical trial legal investigator 's decision</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Diabetes Mellitus , type 2</keyword>
	<keyword>Glitazone</keyword>
</DOC>